JPS6042382A - エンド−８，８−ジアルキル−８−アゾニアビシクロ〔３．２．１〕オクタン−６，７−エキソ−エポキシ−３−アルキルカルボキシレ−ト塩、それ等の製造方法、およびそれ等を活性要素として含む治療用組成物 - Google Patents
エンド−８，８−ジアルキル−８−アゾニアビシクロ〔３．２．１〕オクタン−６，７−エキソ−エポキシ−３−アルキルカルボキシレ−ト塩、それ等の製造方法、およびそれ等を活性要素として含む治療用組成物Info
- Publication number
- JPS6042382A JPS6042382A JP59154184A JP15418484A JPS6042382A JP S6042382 A JPS6042382 A JP S6042382A JP 59154184 A JP59154184 A JP 59154184A JP 15418484 A JP15418484 A JP 15418484A JP S6042382 A JPS6042382 A JP S6042382A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- octane
- endo
- structural formula
- azoniabicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 239000000203 mixture Substances 0.000 title description 5
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 22
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 13
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000004593 Epoxy Substances 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 150000001350 alkyl halides Chemical class 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- FIMXSEMBHGTNKT-UHFFFAOYSA-N Scopine Natural products CN1C2CC(O)CC1C1C2O1 FIMXSEMBHGTNKT-UHFFFAOYSA-N 0.000 claims description 3
- ZGKIYLYSHXFWES-UHFFFAOYSA-N pentanoic acid;hydrobromide Chemical compound Br.CCCCC(O)=O ZGKIYLYSHXFWES-UHFFFAOYSA-N 0.000 claims description 3
- FIMXSEMBHGTNKT-RZVDLVGDSA-N scopine Chemical compound C([C@@H]1N2C)[C@H](O)C[C@@H]2[C@@H]2[C@H]1O2 FIMXSEMBHGTNKT-RZVDLVGDSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000017858 demethylation Effects 0.000 claims 2
- 238000010520 demethylation reaction Methods 0.000 claims 2
- 150000001266 acyl halides Chemical class 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 8
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 8
- 229960000396 atropine Drugs 0.000 description 8
- 210000003405 ileum Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 5
- 229930003347 Atropine Natural products 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229940088506 buscopan Drugs 0.000 description 4
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 4
- 229940102396 methyl bromide Drugs 0.000 description 4
- 230000002911 mydriatic effect Effects 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- 230000001022 anti-muscarinic effect Effects 0.000 description 3
- -1 compound bromide Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001179 pupillary effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- PITHYUDHKJKJNQ-UHFFFAOYSA-N 2-propylpentanoyl chloride Chemical compound CCCC(C(Cl)=O)CCC PITHYUDHKJKJNQ-UHFFFAOYSA-N 0.000 description 1
- JOTRMYCCALXLNJ-UHFFFAOYSA-N 3-ethyl-4-methylpentanoic acid Chemical compound CCC(C(C)C)CC(O)=O JOTRMYCCALXLNJ-UHFFFAOYSA-N 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000219112 Cucumis Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100062121 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cyc-1 gene Proteins 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 235000019647 acidic taste Nutrition 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22238A/83 | 1983-07-26 | ||
| IT22238/83A IT1194343B (it) | 1983-07-26 | 1983-07-26 | Sali di endo-8,8-dialchil-8-azoniabiciclo (3.2.1) ottan-6,7-esso-epossi-3-alchilcarbossilati,processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6042382A true JPS6042382A (ja) | 1985-03-06 |
| JPH0331199B2 JPH0331199B2 (enExample) | 1991-05-02 |
Family
ID=11193504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59154184A Granted JPS6042382A (ja) | 1983-07-26 | 1984-07-26 | エンド−８，８−ジアルキル−８−アゾニアビシクロ〔３．２．１〕オクタン−６，７−エキソ−エポキシ−３−アルキルカルボキシレ−ト塩、それ等の製造方法、およびそれ等を活性要素として含む治療用組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4558054A (enExample) |
| EP (1) | EP0133218B1 (enExample) |
| JP (1) | JPS6042382A (enExample) |
| AT (1) | ATE38989T1 (enExample) |
| AU (1) | AU562763B2 (enExample) |
| CA (1) | CA1248956A (enExample) |
| DE (1) | DE3475402D1 (enExample) |
| DK (1) | DK162285C (enExample) |
| IT (1) | IT1194343B (enExample) |
| NZ (1) | NZ208857A (enExample) |
| ZA (1) | ZA845308B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1190133B (it) * | 1986-06-19 | 1988-02-10 | Chiesi Farma Spa | Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
| US6706726B2 (en) * | 2000-10-14 | 2004-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics which may be used as medicaments as well as processes for preparing them |
| PE20060826A1 (es) * | 2004-12-06 | 2006-10-08 | Smithkline Beecham Corp | Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2962499A (en) * | 1957-07-03 | 1960-11-29 | Endo Lab | Certain esters of tropine and tropinium salts |
| DE1795818C2 (de) * | 1966-01-26 | 1980-07-10 | C.H. Boehringer Sohn, 6507 Ingelheim | Quartärsalze des N-Äthylnorscopolamin |
| DE1670048C3 (de) * | 1966-01-26 | 1980-09-04 | C.H. Boehringer Sohn, 6507 Ingelheim | Neue Norscopolaminderivate |
| GB1413484A (en) * | 1972-04-18 | 1975-11-12 | Angeli Inst Spa | Scopolamine derivatives |
| IT1140998B (it) * | 1980-06-18 | 1986-10-10 | Valeas Ind Chimica E Farmaceut | Sali di endo-8-metil-8-sin-alchil-8-azoniabiciclo aperta par. quadrata 3.2.1. chiusa par. quadrata-ottan-3-alchilcarbossilati, processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo |
-
1983
- 1983-07-26 IT IT22238/83A patent/IT1194343B/it active
-
1984
- 1984-07-05 AT AT84107838T patent/ATE38989T1/de active
- 1984-07-05 EP EP84107838A patent/EP0133218B1/en not_active Expired
- 1984-07-05 DE DE8484107838T patent/DE3475402D1/de not_active Expired
- 1984-07-06 US US06/628,398 patent/US4558054A/en not_active Expired - Fee Related
- 1984-07-10 ZA ZA845308A patent/ZA845308B/xx unknown
- 1984-07-10 NZ NZ208857A patent/NZ208857A/en unknown
- 1984-07-16 CA CA000458985A patent/CA1248956A/en not_active Expired
- 1984-07-25 DK DK363284A patent/DK162285C/da active
- 1984-07-25 AU AU31163/84A patent/AU562763B2/en not_active Ceased
- 1984-07-26 JP JP59154184A patent/JPS6042382A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DK363284D0 (da) | 1984-07-25 |
| AU3116384A (en) | 1985-01-31 |
| DE3475402D1 (en) | 1989-01-05 |
| ATE38989T1 (de) | 1988-12-15 |
| IT8322238A1 (it) | 1985-01-26 |
| EP0133218A3 (en) | 1986-12-30 |
| DK363284A (da) | 1985-01-27 |
| ZA845308B (en) | 1985-02-27 |
| DK162285C (da) | 1992-03-02 |
| CA1248956A (en) | 1989-01-17 |
| EP0133218A2 (en) | 1985-02-20 |
| IT8322238A0 (it) | 1983-07-26 |
| DK162285B (da) | 1991-10-07 |
| US4558054A (en) | 1985-12-10 |
| JPH0331199B2 (enExample) | 1991-05-02 |
| IT1194343B (it) | 1988-09-14 |
| NZ208857A (en) | 1988-05-30 |
| EP0133218B1 (en) | 1988-11-30 |
| AU562763B2 (en) | 1987-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU624130B2 (en) | Gabapentin monohydrate and a process for producing same | |
| EP0491664B1 (en) | Indole derivatives as serotonin antagonists | |
| JPS59104344A (ja) | ロイコトリエン拮抗物質 | |
| HK1000798B (en) | Gabapentin monohydrate and a process for producing the same | |
| BR112021005090A2 (pt) | processo de fabricação para compostos heterocíclicos de 2-nitroimino | |
| JPS6042382A (ja) | エンド−８，８−ジアルキル−８−アゾニアビシクロ〔３．２．１〕オクタン−６，７−エキソ−エポキシ−３−アルキルカルボキシレ−ト塩、それ等の製造方法、およびそれ等を活性要素として含む治療用組成物 | |
| JPS5914033B2 (ja) | 新規な縮合ピリミジン誘導体とその製法 | |
| US3557127A (en) | Substituted cyclohexenes,derivatives thereof and processes for obtaining same | |
| Scaffidi et al. | An expansion of the role of the Corey–Link reaction for the synthesis of α-substituted carboxylic acid esters | |
| PH26422A (en) | 5-substituted ornithine derivatives | |
| EP0286316B1 (en) | 1,2,4-trioxane derivatives | |
| US3401194A (en) | Process for the resolution of stereoisomers from racemic 1-hydroxy-2-amino butane | |
| US2906772A (en) | Resolution of di-2, 2-diphenyl-3-methyl-4-dimethylaminobutyronitrile | |
| US3882164A (en) | Dextrorotatory 3r-n-monomethyl-amino-4c-phenyl-4t-ethoxycarbonicyclohexene-1 and process for the production thereof | |
| JPS59130856A (ja) | １−シアノ−３−（フルオルアルキル）グアニジン | |
| JPS5883694A (ja) | ８−ベンゾイルアミノアルキルピロリチジン誘導体 | |
| US2987519A (en) | 3-alkyl-4, 4-bis (hydroxymethyl)-oxazolidines and process for the preparation thereof | |
| US3637717A (en) | Nicotinic acid ester | |
| PT93675B (pt) | Processo para a preparacao de derivados de acidos aminodicarboxilicos insaturados, contendo fosforo | |
| NO164973B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive gem-dihalo- og tetrahalo-1,2-diamino-4,9,-diaza-dodecaner. | |
| Nicolaides et al. | Synthetic bradykinin analogs | |
| US2786798A (en) | Anhydrides of mucochloric acid | |
| JPH05500797A (ja) | ケトン化合物の調製についての改良された方法 | |
| US2482169A (en) | Acyl derivatives of diaminodiphenylsulfone and preparation thereof | |
| JPS58958A (ja) | 高血圧治療用化合物 |